Desai Rajeev I, Kopajtic Theresa A, French Dawn, Newman Amy H, Katz Jonathan L
Medication Discovery Research Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.
J Pharmacol Exp Ther. 2005 Oct;315(1):397-404. doi: 10.1124/jpet.105.091231. Epub 2005 Jul 13.
Analogs of benztropine (BZT) bind to the dopamine (DA) transporter and inhibit DA uptake but often have behavioral effects that differ from those of cocaine and other DA-uptake inhibitors. To better understand these differences, we examined the relationship between locomotor-stimulant effects of cocaine, 1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)-piperazine (GBR 12909), and BZT analogs [(3alpha-[bis(4'-fluorophenyl)methoxy]-tropane) (AHN 1-055) and (N-allyl-3alpha-[bis(4'-fluorophenyl)methoxy]-tropane) (AHN 2-005)] and their in vivo displacement of the DA transporter ligand [125I]3beta-(4-iodophenyl)-tropan-2beta-carboxylic acid isopropyl ester hydrochloride (RTI-121) in striatum. Cocaine, GBR 12909, and BZT analogs each displaced [125I]RTI-121 and stimulated locomotor activity in a dose- and time-dependent manner. The time course revealed a slower onset of both effects for AHN 1-055 and AHN 2-005 compared with cocaine and GBR 12909. The BZT analogs were less effective than cocaine and GBR 12909 in stimulating locomotor activity. Locomotor stimulant effects of cocaine were generally greater than predicted by the regression of displacement of [125I]RTI-121 and effect at short times after injection and less than predicted at longer times after injection. This result suggests that the apparent rate of occupancy of the DA transporter, in addition to percentage of sites occupied, contributes to the behavioral effects of cocaine. The present results suggest that among drugs that act at the DA transporter, the slower apparent rates of occupancy with the DA transporter by the BZT analogs may contribute in an important way to differences in their effectiveness.
苯托品(BZT)类似物与多巴胺(DA)转运体结合并抑制DA摄取,但往往具有与可卡因及其他DA摄取抑制剂不同的行为效应。为了更好地理解这些差异,我们研究了可卡因、1-{2-[双-(4-氟苯基)甲氧基]乙基}-4-(3-苯基丙基)-哌嗪(GBR 12909)和BZT类似物[(3α-[双(4'-氟苯基)甲氧基]-托烷)(AHN 1-055)和(N-烯丙基-3α-[双(4'-氟苯基)甲氧基]-托烷)(AHN 2-005)]的运动兴奋效应之间的关系,以及它们在体内对纹状体中DA转运体配体[125I]3β-(4-碘苯基)-托烷-2β-羧酸异丙酯盐酸盐(RTI-121)的置换情况。可卡因、GBR 12909和BZT类似物均以剂量和时间依赖性方式置换[125I]RTI-121并刺激运动活性。时间进程显示,与可卡因和GBR 12909相比,AHN 1-055和AHN 2-005的这两种效应起效较慢。BZT类似物在刺激运动活性方面比可卡因和GBR 12909效果更差。可卡因的运动兴奋效应通常大于根据[125I]RTI-121置换与注射后短时间效应的回归预测值,而小于注射后较长时间的预测值。这一结果表明,除了占据的位点百分比外,DA转运体的表观占据率也对可卡因的行为效应有影响。目前的结果表明,在作用于DA转运体的药物中,BZT类似物对DA转运体的表观占据率较慢可能在很大程度上导致了它们有效性的差异。